The incidence of primary antibiotic resistance of helicobacter pylori in Vietnam

Journal of Clinical Gastroenterology

Volumn 47, Issue 3, 2013, Pages 233-238

  Binh, Tran T ^a   Shiota, Seiji ^a   Nguyen, Lam T ^b   Ho, Dung D Q ^a   Hoang, Hai H ^b   Ta, Long ^b   Trinh, Dung T ^c   Fujioka, Toshio ^c   Yamaoka, Yoshio ^a,d  

^a OITA UNIVERSITY   (Japan)

^b CHO RAY HOSPITAL   (Viet Nam)

^c Military Hospital 108   (Viet Nam)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

drug resistance; Helicobacter pylori; Vietnam

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; TETRACYCLINE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CHRONIC GASTRITIS; DUODENUM ULCER; EPSILOMETER TEST; FEMALE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STOMACH MUCOSA; STOMACH ULCER; VIET NAM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; VIETNAM; YOUNG ADULT;

EID: 84874000345     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182676e2b     Document Type: Article

References (55)

1. Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002;2:28-37.
2. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175-1186.
3. Hosking SW, Chung SCS, Yung MY, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. The Lancet. 1994;343:508-510.
4. Shiota S, Yamaoka Y. Management of Helicobacter pylori. F1000 Med Rep. 2010;2-22.
5. Shiota S, Murakami K, Fujioka T, et al. Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective. Expert Rev Gastroenterol Hepatol. 2010;4:149-156.
6. Takenaka R, Okada H, Kato J, et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther. 2007;25:805-812.
7. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772-781.
8. Sugiyama T, Sakaki N, Kozawa H, et al. Sensitivity of biopsy site in evaluating regression of gastric atrophy after Helicobacter pylori eradication treatment. Aliment Pharmacol Ther. 2002;16(suppl 2):187-190.
9. Vannella L, Lahner E, Bordi C, et al. Reversal of atrophic body gastritis after H. pylori eradication at long-term followup. Dig Liver Dis. 2011;43:295-299.
10. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med. 2010;362:1597-1604.
11. Jenks PJ. Causes of failure of eradication of Helicobacter pylori. BMJ. 2002;325:3-4.
12. Qasim A, O'Morain CA. Review article: treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther. 2002;16(suppl 1):24-30.
13. Suzuki T, Matsuo K, Ito H, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006;119:217-224.
14. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374-1384.
15. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother. 1999;43:511-515.
16. van der Wouden EJ, van Zwet AA, Vosmaer GD, et al. Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands. Emerg Infect Dis. 1997;3:385-389.
17. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology. 1998; 115:1278-1282.
18. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007;133:985-1001.
19. Broutet N, Tchamgoue S, Pereira E, et al. Risk factors for failure of Helicobacter pylori therapy - results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2003;17:99-109.
20. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587-1600.
21. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808-1825.
22. Wheeldon TU, Granstrom M, Hoang TT, et al. The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. Aliment Pharmacol Ther. 2004;19:1315-1321.
23. Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol. 2007; 45:4006-4010.
24. Horiki N, Omata F, Uemura M, et al. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter. 2009; 14:86-90.
25. Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, et al. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrob Chemother. 2012;67:170-173.
26. Nguyen TL, Uchida T, Tsukamoto Y, et al. Helicobacter pylori infection and gastroduodenal diseases in Vietnam: a crosssectional, hospital-based study. BMC Gastroenterol. 2010; 10:114-120.
27. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev. 2007;20:280-322.
28. Graham D, Adam E, Reddy G, et al. Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci. 1991;36:1084-1088.
29. Graham D, Malaty H, Evans D, et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology. 1991;100:1495-1501.
30. Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102:760-766.
31. Hoang TT, Bengtsson C, Phung DC, et al. Seroprevalence of Helicobacter pylori infection in urban and rural Vietnam. Clin Diagn Lab Immunol. 2005;12:81-85.
32. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
33. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple firstline therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343-357.
34. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther. 1997;11(suppl 1):43-53.
35. Katelaris PH. Helicobacter pylori: antibiotic resistance and treatment options. J Gastroenterol Hepatol. 2009;24:1155-1157.
36. Gisbert JP, De La Morena F. Systematic review and metaanalysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Therap. 2006;23: 35-44.
37. Gisbert JP. Second-line rescue therapy of Helicobacter pylori infection. Therap Adv Gastroenterol. 2009;2:331-356.
38. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis. 2005;37:821-825.
39. Fujimura S, Kato S, Iinuma K, et al. In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children. J Med Microbiol. 2004;53(pt 10):1019-1022.
40. Bogaerts P, Berhin C, Nizet H, et al. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter. 2006;11:441-445.
41. Kim JM, Kim JS, Kim N, et al. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents. 2006;28:6-13.
42. Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother. 2007;51:346-349.
43. Perna F, Zullo A, Ricci C, et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis. 2007;39:1001-1005.
44. Ahmad N, Zakaria WR, Mohamed R. Analysis of antibiotic susceptibility patterns of Helicobacter pylori isolates from Malaysia. Helicobacter. 2011;16:47-51.
45. Storskrubb T, Aro P, Ronkainen J, et al. Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population. Helicobacter. 2006;11:224-230.
46. Boyanova L, Ilieva J, Gergova G, et al. Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis. A Bulgarian study. J Med Microbiol. 2012;61(pt 1):85-93.
47. Seck A, Mbengue M, Gassama-Sow A, et al. Antibiotic susceptibility of Helicobacter pylori isolates in Dakar, Senegal. J Infect Dev Ctries. 2009;3:137-140.
48. Kato S, Fujimura S. Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years. Pediatr Int. 2010;52:187-190.
49. GerritsMM, Godoy APO, Kuipers EJ, et al.Multiple mutations in or adjacent to the conserved penicillin-binding protein motifs of the penicillin-binding protein 1A confer amoxicillin resistance to Helicobacter pylori. Helicobacter. 2006;11:181-187.
50. Okamoto T, Yoshiyama H, Nakazawa T, et al. A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J Antimicrob Chemother. 2002;50:849-856.
51. Dore MP, Osato MS, Realdi G, et al. Amoxycillin tolerance in Helicobacter pylori. J Antimicrob Chemother. 1999;43:47-54.
52. Yakoob J, Fan X, Hu G, et al. Antibiotic susceptibility of Helicobacter pylori in the Chinese population. J Gastroenterol Hepatol. 2001;16:981-985.
53. Thyagarajan SP, Ray P, Das BK, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: multicentric study. J Gastroenterol Hepatol. 2003;18:1373-1378.
54. Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol. 2009;58(pt 7):930-935.
55. Oh HS, Lee DH, Seo JY, et al. Ten-day sequential therapy is more effective than proton-pump inhibitor-based therapy in Korea: a prospective randomized study. J Gastroenterol Hepatol. 2012;27:504-509.